Japanese doc testifies about inflating placebo counts in Diovan trial

A Japanese physician testified in a case involving Novartis Pharma K.K. and its Diovan (valsartan) drug for high blood pressure that he falsified a report while participating in clinical trials for marketing approval, sources said. The doctor said he inflated the number of placebo patients in the trial. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.